Submit your Manuscript
Novel hit and lead compounds against neglected protozoan diseases
Collection

Novel hit and lead compounds against neglected protozoan diseases

Call for papers in the Journal of Venomous Animals and Toxins including Tropical Diseases

Edited by: Andre G. Tempone and Erika G. Pinto

Neglected tropical diseases (NTDs) are a diverse group of diseases mainly found in tropical and subtropical regions of 149 countries. It is estimated that over 1 billion people are infected with NTDs, with a further 1 billion at risk. Among them, diseases caused by protozoan parasites affect millions of people worldwide, mainly the poorest ones in developing countries. However, such infections have been largely neglected in drug research and development. Most of the current medicines used to treat these diseases are old and have many limitations, including the emergence of drug resistance.

Edited by Prof. Andre G. Tempone (Institute Adolfo Lutz of São Paulo, Brazil) and Dr. Erika G. Pinto (University of Dundee, Scotland), this thematic series aims to build bridges between novel hit or lead compounds and new alternative therapies for neglected protozoan diseases (including malaria). We welcome contributions describing the in vitro and/or in vivo activity of antiprotozoan compounds isolated from natural products (pure and well-characterized substances) and synthetic compounds. Additionally, we also welcome contributions using drug repurposing (or repositioning) approaches, based in approved drugs. The antiprotozoan compounds to be considered as new hit or lead compounds, must be based in strong drug discovery criteria, as: i) potency, ii) selectivity index (or therapeutic index), iii) elimination of interference compounds (pan-assay interference compounds – PAINS), and iv) lack of important structural alerts for known toxic compounds. Contributions describing the mechanism of action (MoA) of drugs, or other active compounds in protozoans are also welcome, using cellular, molecular and/or in silico approaches.

The proposed deadline for submissions is April 30, 2018. The editors invite you to share your knowledge on this exciting subject and submit your manuscript for consideration.

Manuscripts should be formatted according to our submission guidelines and submitted via the online submission system. In the submission system please make sure the correct collection title is chosen from the additional information tab. Please also indicate clearly in the covering letter that the manuscript is to be considered for the "Novel hit and lead compounds against neglected protozoan diseases" series.

If you would like to enquire about the suitability of a manuscript for consideration, please email a pre-submission enquiry to editorial@jvat.org.br.

Research 

Second-generation pterocarpanquinones: synthesis and antileishmanial activity

Viviane dos Santos Faiões, Lívia C. R. M. da Frota, Edézio Ferreira Cunha-Junior, Julio C. F. Barcellos, Thayssa Da Silva, Chaquip Daher Netto, Silvia Amaral Gonçalves Da-Silva, Alcides J. M. da Silva, Paulo R. R. Costa and Eduardo Caio Torres-Santos
Research 

Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study

Daiane Dias Ferreira, Juliana Tonini Mesquita, Thais Alves da Costa Silva, Maiara Maria Romanelli, Denise da Gama Jaen Batista, Cristiane França da Silva, Aline Nefertiti Silva da Gama, Bruno Junior Neves, Cleber Camilo Melo-Filho, Maria de Nazare Correia Soeiro, Carolina Horta Andrade and Andre Gustavo Tempone
Research 

Activity of the antiarrhythmic drug amiodarone against Leishmania (L.) infantum: an in vitro and in vivo approach

Erika G. Pinto and Andre G. Tempone
Research 

Neolignans isolated from twigs of Nectandra leucantha Ness & Mart (Lauraceae) displayed in vitro antileishmanial activity

Simone S Grecco, Thais A Costa-Silva, Fernanda S Sousa, Stefano B Cargnelutti, Eric Umehara, Poliana S Mendonça, Andre G Tempone and Joao Henrique G Lago
Research 

4-Phenyl-1,3-thiazole-2-amines as scaffolds for new antileishmanial agents

Carina Agostinho Rodrigues, Paloma Freire dos Santos, Marcela Oliveira Legramanti da Costa, Thais Fernanda Amorim Pavani, Patrícia Xander, Mariana Marques Geraldo, Ana Mengarda, Josué de Moraes and Daniela Gonçales Galasse Rando
Research 

Impact of a utologous whole blood administration upon experimental mouse models of acute Trypanosoma cruzi infection

Beatriz Philot Pavão, Kelly Cristina Demarque, Marcos Meuser Batista, Gabriel Melo de Oliveira, Cristiane França da Silva, Francisca Hildemagna Guedes da Silva, Luzia Fátima Gonçalves Caputo, Cynthia Machado Cascabulho, Marcello André Barcinski and Maria de Nazaré Correia Soeiro
Research 

Effect of phospholipase A2 inhibitors during infection caused by Leishmania (Leishmania) amazonensis

Maria L. A. C. Bordon, Márcia D. Laurenti, Susan Pereira Ribeiro, Marcos H. Toyama, Daniela de O. Toyama and Luiz Felipe D. Passero
Review 

Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases

Greta Volpedo, Lourena Costa, Nathan Ryan, Gregory Halsey, Abhay Satoskar and Steve Oghumu
Research 

Nitro-Heterocyclic compounds induce apoptosis-like effects in Leishmania (L.) amazonensis promastigotes

Daiane Barros Dias Mendonça, Renata Ellen Costa Silva, Fanny Palace-Berl, Cleusa F. H. Takakura, Sandra Regina C. Soares, Lucia Maria Almeida Braz, Leoberto Costa Tavares and Jose Angelo Lauletta Lindoso
Research 

Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice

Samanta Etel Treiger Borborema, João Alberto Osso Junior, Heitor Franco de Andrade Junior and Nanci do Nascimento